Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3
Not yet recruiting
- Conditions
- Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 2400
- Registration Number
- NCT06966700
Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)
Phase 2
Recruiting
- Conditions
- ER+/HER2- Breast Cancer
- Interventions
- Procedure: HIFUDrug: nab-Paclitaxel (nab-P)
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 140
- Registration Number
- NCT06964906
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
Serplulimab Combined with Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- HR+/HER2- Breast Cancer
- Interventions
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 357
- Registration Number
- NCT06860529
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
Phase 2
Recruiting
- Conditions
- Early Triple Negative Breast Cancer
- Interventions
- Drug: Doxorubicin (hydrochloride)Drug: Olaparib (if approved/available locally)
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06829199
- Locations
- 🇺🇸
Optum Care Cancer Center ( Site 0004), Las Vegas, Nevada, United States
🇨🇳National Cheng Kung University Hospital ( Site 0901), Tainan, Taiwan
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Phase 2
Recruiting
- Conditions
- Breast NeoplasmsBreast Cancer
- Interventions
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 372
- Registration Number
- NCT06797635
- Locations
- 🇺🇸
Northwest Cancer Specialists (Compass Oncology) ( Site 8003), Tigard, Oregon, United States
🇺🇸Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003), Billings, Montana, United States
🇺🇸SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, United States
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
Phase 1
Not yet recruiting
- Conditions
- OsteosarcomaSoft Tissue Sarcoma (STS)
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 448
- Registration Number
- NCT06699576
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Phase 2
Not yet recruiting
- Conditions
- Rare Tumour
- Interventions
- Drug: Other
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- HR+/HER2- Breast CancerBreast Cancer
- Interventions
- Procedure: High Intensity Focused Ultrasoun（HIFU）
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Target Recruit Count
- 29
- Registration Number
- NCT06470633
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- HR+HER2- Breast CancerEarly Breast CancerNeoadjuvant Therapy
- Interventions
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 76
- Registration Number
- NCT06404463
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT06389006
- Locations
- 🇨🇳
Jiong Wu, Shanghai, Fudan University Shanghai Cancer Center, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath